TY - JOUR
T1 - Poor postpartum sleep quality predicts subsequent postpartum depressive symptoms in a high-risk sample
AU - McEvoy, Katherine M.
AU - Rayapati, Divya
AU - Washington Cole, Katie O.
AU - Erdly, Courtney
AU - Payne, Jennifer L.
AU - Osborne, Lauren M.
N1 - Funding Information:
Work for this study was performed at Johns Hopkins University School of Medicine, Women’s Mood Disorders Center, Department of Psychiatry and Behavioral Sciences. In the past year, Dr. Jennifer Payne has performed legal consulting work for Abbott Pharmaceuticals and Johnson and Johnson. She also has a patent on epigenetic biomarkers for postpartum depression. The remaining authors report no conflicts of interest. Dr. Osborne’s work was supported by NIH 1K23 MH110607-01A1 and the Doris Duke Early Clinician Investigator Award. Dr. Payne’s work was supported by NIMH K23 MH074799. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Funding Information:
The authors thank Samantha Meilman and Meeta Pangtey, research staff who assisted with the collection of data and preparation of this manuscript Work for this study was performed at Johns Hopkins University School of Medicine, Women's Mood Disorders Center, Department of Psychiatry and Behavioral Sciences. In the past year, Dr. Jennifer Payne has performed legal consulting work for Abbott Pharmaceuticals and Johnson and Johnson. She also has a patent on epigenetic biomarkers for postpartum depression. The remaining authors report no conflicts of interest. Dr. Osborne's work was supported by NIH 1K23 MH110607-01A1 and the Doris Duke Early Clinician Investigator Award. Dr. Payne's work was supported by NIMH K23 MH074799. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Publisher Copyright:
© 2019 American Academy of Sleep Medicine. All rights reserved.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Study Objectives: Postpartum depression (PPD) occurs in 15% to 20% of mothers worldwide and is associated with adverse outcomes for mother and child. Prior research has established a relationship between concurrent sleep quality and PPD. We conducted a secondary analysis in 45 women with mood disorders to study overall sleep quality (and individual components of sleep), measured in the early postpartum period, as a predictor of subsequent PPD. Methods: We measured sleep quality using the Pittsburgh Sleep Quality Index (PSQI; subscale and total scores) at 1 month postpartum (and during the third trimester). We measured depressive symptoms using the Inventory of Depressive Symptoms, Self-Report (IDS-SR) at 3 months postpartum. We used bivariate and multivariate linear regression models to study the association between PSQI and IDS scores. Results: We found that higher global PSQI scores as well as higher component scores for self-reported sleep quality, sleep latency, sleep efficiency, sleep medication usage, and daytime dysfunction, measured 1 month postpartum, were associated with increased IDS scores (at 3 months postpartum (P =.01, .01, .01, .003, < .001, respectively). We did not find an association between poor sleep quality in the third trimester and PPD. Conclusions: Poor sleep quality in the early postpartum period independently predicts development of later PPD. This is clinically significant and highlights the importance of sleep interventions as an immediate postpartum therapeutic tool.
AB - Study Objectives: Postpartum depression (PPD) occurs in 15% to 20% of mothers worldwide and is associated with adverse outcomes for mother and child. Prior research has established a relationship between concurrent sleep quality and PPD. We conducted a secondary analysis in 45 women with mood disorders to study overall sleep quality (and individual components of sleep), measured in the early postpartum period, as a predictor of subsequent PPD. Methods: We measured sleep quality using the Pittsburgh Sleep Quality Index (PSQI; subscale and total scores) at 1 month postpartum (and during the third trimester). We measured depressive symptoms using the Inventory of Depressive Symptoms, Self-Report (IDS-SR) at 3 months postpartum. We used bivariate and multivariate linear regression models to study the association between PSQI and IDS scores. Results: We found that higher global PSQI scores as well as higher component scores for self-reported sleep quality, sleep latency, sleep efficiency, sleep medication usage, and daytime dysfunction, measured 1 month postpartum, were associated with increased IDS scores (at 3 months postpartum (P =.01, .01, .01, .003, < .001, respectively). We did not find an association between poor sleep quality in the third trimester and PPD. Conclusions: Poor sleep quality in the early postpartum period independently predicts development of later PPD. This is clinically significant and highlights the importance of sleep interventions as an immediate postpartum therapeutic tool.
KW - Perinatal
KW - Postpartum
KW - Postpartum depression
KW - Risk factor
KW - Sleep quality
UR - http://www.scopus.com/inward/record.url?scp=85072345552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072345552&partnerID=8YFLogxK
U2 - 10.5664/jcsm.7924
DO - 10.5664/jcsm.7924
M3 - Article
C2 - 31482808
AN - SCOPUS:85072345552
SN - 1550-9389
VL - 15
SP - 1303
EP - 1310
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 9
ER -